· Practitioner's Docket No. MPI1997-018CP1DV1

IN THE CLAIMS:

Kindly cancel Claims 16-31 and 47-88.

Status of CLAIMS

- 1. A method for identifying a compound capable of modulating a I5E activity, comprising:
 - a. contacting a compound to a cell that expresses a I5E gene;
 - b. measuring the level of I5E gene expression in the cell; and
 - c. comparing the level obtained in (b) to I5E gene expression level obtained in the absence of the compound;

such that if the level obtained in (b) differs from that obtained in the absence of the compound, a compound capable of modulating a I5E activity has been identified.

- 2. The method of Claim 32 wherein the compound increases the level of I5E gene expression.
- 3. The method of Claim 32 wherein the compound decreases the level of I5E gene expression.
- 4. The method of Claim 32 in which expression of the I5E gene is detected by measuring I5E mRNA transcripts.
- 5. The method of Claim 32 in which expression of the I5E gene is detected by measuring I5E gene product.
 - 6. The method of Claim 32 wherein the compound is a small organic molecule.
- 7. A method for identifying a compound capable of treating an immune, central nervous system or metabolic disorder, comprising:
 - a. contacting a compound to a cell that expresses a I5E gene;
 - b. measuring the level of I5E gene expression in the cell; and
 - c. comparing the level obtained in (b) to I5E gene expression level obtained in the absence of the compound;

such that if the level obtained in (b) differs from that obtained in the absence of the compound, a compound capable of treating an immune, central nervous system or metabolic disorder has been identified.

· Practitioner's Docket No. MPI1997-018CP1DV1

- 8. The method of Claim 38 wherein the central nervous system disorder is schizophrenia, cognitive disorders multiple sclerosis or depression.
 - 9. The method of Claim 38 wherein the immune disorder is an inflammatory disorder.
 - 10. The method of Claim 38 wherein the metabolic disorder is a body weight disorder.
- 11. The method of Claim 38 wherein the compound increases the level of I5E gene expression.
- 12. The method of Claim 38 wherein the compound decreases the level of I5E gene expression.
- 13. The method of Claim 38 in which expression of the I5E gene is detected by measuring I5E mRNA transcripts.
- 14. The method of Claim 38 in which expression of the I5E gene is detected by measuring I5E gene product.
 - 15. The method of Claim 38 in which the compound is a small organic molecule.